Login to Your Account



Will Tangled Web Ensnare Diarrhea Drug?

Salix Trumps Napo, Submits Crofelemer NDA for Review

By Marie Powers
Staff Writer

Thursday, December 15, 2011

One month after partner Napo Pharmaceuticals Inc. claimed to terminate their three-year-old collaboration to develop crofelemer for HIV-associated diarrhea, Salix Pharmaceuticals Ltd. plowed ahead by submitting a new drug application (NDA) for the drug to the FDA. The filing set in motion the 60-day clock for the FDA to conduct its review and determine whether to accept the NDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription